De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1943-4596
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer ; volume:13 ; number:3 ; day:14 ; month:6 ; year:2021 ; pages:151-156 ; date:9.2021
Current breast cancer reports ; 13, Heft 3 (14.6.2021), 151-156, 9.2021
- Creator
-
Gonzalez, Lorena
Mortimer, Joanne
Kruper, Laura
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12609-021-00421-3
- URN
-
urn:nbn:de:101:1-2021110609145093903156
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gonzalez, Lorena
- Mortimer, Joanne
- Kruper, Laura
- SpringerLink (Online service)
Other Objects (12)
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Distribution of PD-L1, TROP2 and HER2- “lowness” in early triple-negative breast cancer: an opportunity for treatment de-escalation
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Metastatic Triple-Negative Breast Cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance